Dovato: New FDA Approved HIV-1 Drug
by Manzoor Khan Pharmacist
FDA approves the First once daily single tablet two drugs regime for the treatment of HIV-1
Recommended Features
- Generic: dolutegravir and lamivudine
- Drug Class: Combination of drugs
- Use: HIV-1 infection in adults
- Manufacturer: ViiV Healthcare
- Approval Date: 8th April 2019
Review on Dovato: New FDA Approved HIV-1 Drug
Dovato is the Brand name for the combination of two medications, such as dolutegravir and lamivudine. The US Food And Drugs Administration (FDA) has approved the treatment of HIV infection based on two drugs and Single tablet Regime (STR).It is the first, once daily, single tablet for HIV1 Patients.
The most common adverse reactions with Dovato were
Headache,
Diarrhea,
Nausea,
Weakness
Fatigue.
For full review visit DrugsBank here
https://www.drugsbanks.com/dovato-dolutegravir-lamivudine/
Related to Dovato: New FDA Approved HIV-1 Drug
Sponsor Ads
Created on Apr 26th 2019 13:27. Viewed 426 times.
Comments
No comment, be the first to comment.